CaaMTech first received a patent in support of research in 2021. Article published Wednesday on the Greenstate website He explains that the company is “developing pharmaceutical drugs for mental health conditions such as depression and obsessive-compulsive disorder,” and is now “investigating the therapeutic value of psilocybin in combination with cannabis.”
“Through their research, CaaMTech has isolated psilocybin derivatives, cannabinoids, and terpenes,” Greenstate explained.
In the 2021 announcement of the patent, “The company’s goal from day one has been to get as much of CaaMTech’s scientific innovation as possible into our intellectual property portfolio as we develop the next generation of pharmacokinetics,” said Dr. Andrew Chadin, Founder and CEO of CaaMTech.
“Our first patent application gave a boost of energy to the team that has worked so hard over the past four years to get it to the finish line,” Shadine He said in advertising. “With hundreds of applications under trial, this is a great start.”
“Strong patent protection and basic research give our drugs the essential support they need to move forward into clinical trials and become FDA-approved,” he added. “Compositions and Methods Incorporating a Psilocybin Derivative” covers (among other topics) the synergistic effects of cannabinoids on serotonin receptor activation when administered in combination with a serotonin agonist. In simpler terms, CaaMTech has shown that cannabinoids work synergistically with the psychedelic tryptamine in producing its effects. In doing so, CaaMTech has demonstrated the potential of two drugs once declared by the United States Federal Government to have “no known medical value” for treating some of the world’s most challenging mental health problems.
The ad reads, “Notice of allowance [from the the US Patent and Trademark Office (USPTO)] It’s a watershed moment for CaaMTech’s intellectual property division, which has filed well over a hundred additional patent applications since filing in 2017.”
“The premium is the last hurdle of examination before issuing a patent,” the advertisement states.
Since this patent was approved in 2021, Greenstate reports that “CaaMTech has shared findings regarding 4-PrO-DMT as a new synthetic alternative to psilocybin, among other things.”
Separate efforts may complement this work, such as a research survey from SABI Mind that covers myriad topics, such as general acceptance or disregard for synthetic alternatives to compounds like psilocybin. These steps, combined with political action, create broader access corridors for patients seeking for trustworthy, science-based anesthetic therapies.” You mentioned the port.
Developing the complex will not be easy. As explained by MJBizDaily, there are “serious hurdles to creating a combo pool.”
“Cannabis and drugs act on different receptors in the brain. Cannabinoids such as THC bind primarily to the CB1 cannabinoid receptor; CBC binds primarily to the CB2 receptor. Drugs such as psilocybin bind primarily to the serotonin 5-HT2A receptor,” the outlet reported.
“But there has been research showing that cannabinoid CBDs can bind to serotonin, and that when serotonin joins with CB2 cannabinoid receptors, the resulting combination can do things that none of the receptors can do on their own… Powered by the potential of a combo, The medical cannabis community is growing increasingly enthusiastic. For example, cannabis combined with cannabinoid drugs has been found to significantly shrink tumorigenesis in breast cancer.”
CaaMTech, based in Issaquah, Washingtonbills itself as “the premier drug discovery and improvement company focused on engineering pharmacokinetics that meet the standards of modern medicine.”
